Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Routine +

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health

Early-stage preclinical milestone adds to pipeline, but stock has already priced in a +200% run; execution risk remains high.

By The Northwire Desk — AI Analysis Jun 18, 2026 · 09:02 TRIP · 0.025 Red Light Holland Corp.
Executive Summary
  • Red Light Holland reports positive preclinical results from Magdalena Biosciences (a joint venture with Jaguar Health) for a novel whole-leaf coca extract.
  • The extract prevented weight gain in mice on a high-fat diet without suppressing appetite or increasing physical activity, targeting post-GLP-1 weight maintenance.
  • Development is advancing under the FDA's Botanical Guidance pathway. The 20-day study was conducted at the University of Calgary using legally sourced Peruvian coca leaves.
  • Corporate structure: Magdalena is a U.S.-based JV formed in 2023 by Filament Health (wholly owned by Red Light) and Jaguar Health.
  • Funding: One Small Planet (founded by Will Peterffy) committed US$1,000,000 to the JV.
  • Strategic context: Red Light is leveraging its April 2026 acquisition of Filament Health to expand into pharmaceutical-grade manufacturing, regulatory compliance, and clinical research for botanical medicines.
Material Impact
  • The news is a preclinical milestone, not an earnings release. It confirms pipeline progress for a novel weight-maintenance therapy targeting the large post-GLP-1 market.
  • The stock had already run +200% into the print, implying the market expected continued pipeline validation and M&A integration benefits.
  • The $1M JV funding from One Small Planet is modest and does not materially change the cash runway.
  • The underlying facts are positive but incremental. The market reaction (not in data) will likely be muted or negative if the stock fails to hold the $0.03 level, given the high expectations baked in.
  • The news is Routine - Positive. It reinforces the strategic pivot but does not alter the fundamental risk/reward profile or provide near-term revenue visibility.
TRIP · Price
Company Overview
  • Red Light Holland Corp. (CSE: TRIP) is a Canadian company that has pivoted from consumer retail (mushroom grow kits, functional gummies) to a regulated psychedelic and botanical drug development platform.
  • Core assets include Filament Health's patented botanical psilocybin candidate PEX010, a Health Canada Level 8 Dealer's Licence, GMP manufacturing capabilities, and a portfolio of 76 patents.
  • The company supplies PEX010 to 80+ global academic and clinical studies, focusing on depression, PTSD, substance use disorders, and cancer-related distress.
  • Recent strategic moves include the acquisition of Filament Health (April 2026), partnerships with Kala Bio for AI-driven clinical planning, and the formation of Magdalena Biosciences for a coca extract weight-maintenance program.
Read the original news release →

More from Red Light Holland Corp.

Jun 08, 2026 · 07:31

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Other Jun 04, 2026 · 07:32

Red Light Holland Secures UCSF Supply Deal for PEX010, But Clinical Progress Remains Incremental Amid Dilution Concerns

Other May 25, 2026 · 08:40

Red Light Holland Expands Filament Health Psychedelic Supply Footprint in New Zealand

Other May 14, 2026 · 08:31

Red Light Holland expands its clinical psilocybin network, but mounting share dilution and a transition to pharma leave investors waiting for a clear commercial catalyst.

Production / Operations May 13, 2026 · 09:13

Red Light Holland Consolidates Psychedelic Platform Post-Acquisition Amidst Management Transition

Financings May 08, 2026 · 07:31

Red Light Holland Validates Filament Acquisition with Cocaine Trial Data, Yet Dilution Risks Loom

Other